Articles related to BLOOD CANCERS

To gain access to its primary experimental medication for a rare blood cancer and complement Blenrep, currently indicated as a treatment for patients with relapsed or refractory multiple myeloma who received at least four prior therapies, the company decided to purchase American pharmaceutical company Sierra Oncology in April. However, in patients with relapsed or refractory multiple myeloma, Blenrep did not achieve the primary endpoint of progression-free survival, according to a statement from GSK, which saw its shares fall 3% upon the announcement.

The CRc rate was higher with GIL + AZA than with AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy. In addition, OS did not differ significantly between GIL + AZA and AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy.

Lauren C. Pinter-Brown, MD, the Health Sciences Professor of Medicine and Dermatology at the Chao Family Comprehensive Cancer Center at the University of California, Irvine, discusses the most common types of T-cell lymphoma, recent changes to its diagnosis and classification, standard approaches, treatment challenges, unmet needs, new treatments, promising areas of research, and other recommendations regarding its management.

HBCLs, not-otherwise specified (NOS), are rare and heterogeneous; other than having germinal center B-cell phenotype, and in up to 45%, a single-hit MYC rearrangement, they have no unifying immunophenotypic or cytogenetic characteristics. This review discusses the current clinicopathologic concept of HGBL, NOS, and looks at potential future taxonomy enrichments based on emerging molecular diagnostics.

Over a 4-year period, 500 patients were distributed equally between the two regimens. Two-year OS, relapse rates, and non-relapse mortality were similar between the two regiments, indicating that the busulfan regimen is non-inferior to the traditional TBI regimen.

The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone(hyper-CVAD) regimen has undergone many modifications to make administration more palatable and user-friendly for patients and physicians in community and academic settings, including refinements to avoid complications and reduce adverse events. Dr. Elias Jabbour of MD Anderson Cancer Center reviews a number of these modifications in this interview.